Physician profile

Dennis Gage

Endocrinology, Diabetes & Metabolism · New York, NY

NPI 1023014776

$5,179.49

in general payments reported to CMS, 2019-2025

32 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $612.28 2019-2020
Tosoh Bioscience, INC. $557.00 2019
Boehringer Ingelheim Pharmaceuticals, INC. $497.51 2019-2020
Abbvie INC. $462.31 2019-2020
Astrazeneca Pharmaceuticals LP $432.24 2019-2020
Sanofi-Aventis U.S. LLC $414.47 2019-2020
Lilly USA, LLC $365.60 2019-2020
Merck Sharp & Dohme LLC $267.71 2019-2020
Amgen INC. $237.74 2019-2020
Antares Pharma, INC. $143.57 2019-2020
Shire North American Group INC $130.96 2019
Ibsa Pharma INC. $128.53 2019
Mannkind Corporation $117.91 2019-2021
Janssen Pharmaceuticals, INC $113.37 2019-2020
Aytu Biopharma, INC. $110.18 2019-2020
Show all 32 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dennis Gage

$5,179.49

in general payments reported 2019-2025

Years
2019-2021
Top company
Novo Nordisk INC

https://glasscript.com/doctor/318535/dennis-gage

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.